Compare Abbott Laboratories (ABT) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Under Armour Inc Class A — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while Under Armour Inc Class A trades at $6.49 (market cap $2.87B). The key difference: Abbott Laboratories is far larger — about 58.2× Under Armour Inc Class A's market cap, and Abbott Laboratories pays a 2.63% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| ABT | UAA | |
|---|---|---|
Market Cap | $166.94B | $2.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $8.14 |
52-Week Low | $82.57 | $4.17 |
Enterprise Value | $193.69B | $4.50B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Under Armour (UAA) trades at $6.74, up 1.66% today, with a bullish technical signal from moving averages but bearish oscillators. Recent earnings show mixed results, with Q4 2026 beating expectations but Q1 2026 missing. The company faces declining revenue and negative net income margins, though international growth and a new Dodge collaboration offer potential catalysts. Cash flow remains negative, and the balance sheet shows rising debt-to-asset ratios, indicating financial strain.
The outlook is cautious due to weak North American sales and margin pressure, but analyst consensus leans hold with a $5.96 price target. Risks include consumer spending softness and execution challenges, while opportunities lie in international expansion and strategic partnerships. Investors should weigh deteriorating fundamentals against potential turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
